How Endogenous Hormone Release Differs from Synthetic GLP-1 Drugs The study centers on a difference between endogenous GLP-1 stimulation, the bodys own secretion of glucagon-like peptide-1 from intestinal cells, and prescription receptor agonists
[1] [2] The affected pathways reportedly include DNA repair, antioxidant defense, anti-inflammatory signaling, and tissue remodeling, and related work extended this analysis to nervous-system genes
A 2024 study published in the ASMBS found that patients who used GLP-1 medications before surgery had a lower risk of post-operative complications
That realization is pushing medicine toward a future of personalized obesity care, where treatment is tailored to an individuals specific biology rather than relying on one blockbuster drug for everyone
Two standard drinks (roughly 24g of ethanol) suppress GH secretion equally whether consumed as beer, wine, or spirits
Phase 3 trials are the large-scale, randomised controlled studies required to establish efficacy and safety across diverse patient populations before a regulatory submission can be made